Factor 8 Hemlibra denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Label Hemlibra Experimental — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) holds FDA approval for prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A with or without factor VIII inhibitors. An "experimental or investigational" denial for an FDA-approved therapy in a labeled indication is almost always either a claims-processing error or an application of the experimental designation to a use outside the labeled population. Confirm which applies before drafting your appeal.

## Why This Denial Is Appealable

For an FDA-approved drug used within its labeled indication, an experimental denial lacks a sound regulatory basis and is a strong candidate for reversal on internal appeal. Even for off-label uses, many plans are required to cover medically necessary off-label use supported by recognized drug compendia or peer-reviewed literature, particularly for serious conditions. An independent external reviewer will apply objective clinical evidence standards, not the plan's internal policy preference.

## Federal Appeal Framework

• ERISA §503: Full-and-fair internal review; file within 180 days of the denial notice.
• ACA §2719: Binding independent external review after internal exhaustion, typically within four months of a final internal denial.
• Expedited review: Available if standard timelines would place the patient at serious clinical risk; typically 72-hour resolution.
• Mental Health Parity / MHPAEA: Not directly applicable here, but note that experimental-designation criteria must be applied no more stringently than for analogous non-specialty conditions under applicable parity rules.

## Concrete Appeal Steps and Timeline

1. Confirm the denial letter states "experimental/investigational" as the basis. 2. Identify whether the prescribed use is within the FDA-approved label or off-label. 3. Request Aetna's experimental-and-investigational policy and the specific criteria that were applied. 4. File an internal appeal with documentation demonstrating FDA approval status and clinical indication. 5. If denied internally, file for external review within four months.

## Documentation to Gather

• FDA approval confirmation: Reference the current FDA-approved prescribing information for Hemlibra and confirm the patient's diagnosis and use falls within the labeled indication.
• Diagnosis documentation: Hemophilia A diagnosis with inhibitor status confirmed by the treating hematologist.
• Prescriber letter: The hematologist should explicitly state the use is within the FDA-approved label (or, if off-label, cite the recognized clinical guideline organization — e.g., the applicable ASH or WFH guideline — and explain why it is the standard of care for this patient).
• Clinical severity: Bleed frequency, joint damage records, and prior treatment history.

## Criteria-Mapping Structure

Obtain Aetna's experimental-and-investigational policy. Map each criterion it requires for a therapy to be classified as experimental against the documented FDA-approval status and current clinical guideline endorsement. Where the plan's own criteria are not met by the experimental designation, state so explicitly in the appeal letter. This mismatch is often sufficient for reversal at the internal stage.